Eliem Therapeutics Total Liabilities and Share Holders Equity 2021-2024 | CLYM
Eliem Therapeutics total liabilities and share holders equity from 2021 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Eliem Therapeutics Annual Total Liabilities and Share Holders Equity (Millions of US $) |
2023 |
$110 |
2022 |
$135 |
2021 |
$173 |
2020 |
$25 |
Eliem Therapeutics Quarterly Total Liabilities and Share Holders Equity (Millions of US $) |
2024-06-30 |
$226 |
2024-03-31 |
$109 |
2023-12-31 |
$110 |
2023-09-30 |
$113 |
2023-06-30 |
$116 |
2023-03-31 |
$122 |
2022-12-31 |
$135 |
2022-09-30 |
$141 |
2022-06-30 |
$150 |
2022-03-31 |
$162 |
2021-12-31 |
$173 |
2021-09-30 |
$182 |
2021-06-30 |
$108 |
2021-03-31 |
$0 |
2020-12-31 |
|
2020-09-30 |
$0 |
2020-06-30 |
$0 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-DRUGS |
$0.342B |
$0.000B |
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|